Opus Genetics Stock Net Income
| IRD Stock | 2.56 0.06 2.40% |
As of the 27th of January, Opus Genetics holds the Risk Adjusted Performance of 0.0901, semi deviation of 3.57, and Coefficient Of Variation of 897.54. Opus Genetics technical analysis gives you tools to exploit past prices in attempt to determine a pattern that determines the direction of the company's future prices. Please check Opus Genetics information ratio, value at risk, as well as the relationship between the Value At Risk and expected short fall to decide if Opus Genetics is priced some-what accurately, providing market reflects its current price of 2.56 per share. Please also confirm Opus Genetics total risk alpha, which is currently at 0.0534 to check out the company can sustain itself at a future point.
Opus Genetics Total Revenue |
|
Gross Profit | Market Capitalization | Enterprise Value Revenue 10.0322 | Revenue | Earnings Share (1.86) |
| Last Reported | Projected for Next Year | ||
| Net Loss | -51.8 M | -49.2 M | |
| Net Loss | -51.8 M | -49.2 M | |
| Net Loss | (1.94) | (2.04) | |
| Net Income Per E B T | 0.90 | 0.79 |
Opus | Net Income | Build AI portfolio with Opus Stock |
Latest Opus Genetics' Net Income Growth Pattern
Below is the plot of the Net Income of Opus Genetics over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Opus Genetics financial statement analysis. It represents the amount of money remaining after all of Opus Genetics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Opus Genetics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Opus Genetics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (57.53 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Opus Net Income Regression Statistics
| Arithmetic Mean | (17,270,686) | |
| Geometric Mean | 12,194,612 | |
| Coefficient Of Variation | (129.15) | |
| Mean Deviation | 18,054,145 | |
| Median | (6,169,000) | |
| Standard Deviation | 22,305,300 | |
| Sample Variance | 497.5T | |
| Range | 75.4M | |
| R-Value | (0.60) | |
| Mean Square Error | 339.1T | |
| R-Squared | 0.36 | |
| Significance | 0.01 | |
| Slope | (2,654,276) | |
| Total Sum of Squares | 7960.4T |
Opus Net Income History
Other Fundumenentals of Opus Genetics
Opus Genetics Net Income component correlations
Opus Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Opus Genetics is extremely important. It helps to project a fair market value of Opus Stock properly, considering its historical fundamentals such as Net Income. Since Opus Genetics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Opus Genetics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Opus Genetics' interrelated accounts and indicators.
Click cells to compare fundamentals
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
The market value of Opus Genetics is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics' value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics' market value can be influenced by many factors that don't directly affect Opus Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Opus Genetics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Opus Genetics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Opus Genetics.
| 10/29/2025 |
| 01/27/2026 |
If you would invest 0.00 in Opus Genetics on October 29, 2025 and sell it all today you would earn a total of 0.00 from holding Opus Genetics or generate 0.0% return on investment in Opus Genetics over 90 days. Opus Genetics is related to or competes with Acumen Pharmaceuticals, Seer, Agenus, Inovio Pharmaceuticals, VistaGen Therapeutics, TuHURA Biosciences, and Alector. Opus Genetics is entity of United States More
Opus Genetics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Opus Genetics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Opus Genetics upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 3.88 | |||
| Information Ratio | 0.0926 | |||
| Maximum Drawdown | 26.5 | |||
| Value At Risk | (6.10) | |||
| Potential Upside | 6.7 |
Opus Genetics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Opus Genetics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Opus Genetics' standard deviation. In reality, there are many statistical measures that can use Opus Genetics historical prices to predict the future Opus Genetics' volatility.| Risk Adjusted Performance | 0.0901 | |||
| Jensen Alpha | 0.3849 | |||
| Total Risk Alpha | 0.0534 | |||
| Sortino Ratio | 0.1028 | |||
| Treynor Ratio | 0.3934 |
Opus Genetics January 27, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0901 | |||
| Market Risk Adjusted Performance | 0.4034 | |||
| Mean Deviation | 3.27 | |||
| Semi Deviation | 3.57 | |||
| Downside Deviation | 3.88 | |||
| Coefficient Of Variation | 897.54 | |||
| Standard Deviation | 4.3 | |||
| Variance | 18.53 | |||
| Information Ratio | 0.0926 | |||
| Jensen Alpha | 0.3849 | |||
| Total Risk Alpha | 0.0534 | |||
| Sortino Ratio | 0.1028 | |||
| Treynor Ratio | 0.3934 | |||
| Maximum Drawdown | 26.5 | |||
| Value At Risk | (6.10) | |||
| Potential Upside | 6.7 | |||
| Downside Variance | 15.03 | |||
| Semi Variance | 12.73 | |||
| Expected Short fall | (3.65) | |||
| Skewness | 0.6189 | |||
| Kurtosis | 2.14 |
Opus Genetics Backtested Returns
Opus Genetics appears to be very risky, given 3 months investment horizon. Opus Genetics maintains Sharpe Ratio (i.e., Efficiency) of 0.12, which implies the firm had a 0.12 % return per unit of risk over the last 3 months. By analyzing Opus Genetics' technical indicators, you can evaluate if the expected return of 0.52% is justified by implied risk. Please evaluate Opus Genetics' Coefficient Of Variation of 897.54, risk adjusted performance of 0.0901, and Semi Deviation of 3.57 to confirm if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Opus Genetics holds a performance score of 9. The company holds a Beta of 1.19, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Opus Genetics will likely underperform. Please check Opus Genetics' expected short fall, and the relationship between the value at risk and daily balance of power , to make a quick decision on whether Opus Genetics' historical price patterns will revert.
Auto-correlation | 0.50 |
Modest predictability
Opus Genetics has modest predictability. Overlapping area represents the amount of predictability between Opus Genetics time series from 29th of October 2025 to 13th of December 2025 and 13th of December 2025 to 27th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Opus Genetics price movement. The serial correlation of 0.5 indicates that about 50.0% of current Opus Genetics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.5 | |
| Spearman Rank Test | 0.26 | |
| Residual Average | 0.0 | |
| Price Variance | 0.03 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Opus Operating Income
Operating Income |
|
Based on the recorded statements, Opus Genetics reported net income of (57.53 Million). This is 116.86% lower than that of the Pharmaceuticals sector and 182.13% lower than that of the Health Care industry. The net income for all United States stocks is 110.08% higher than that of the company.
Opus Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Opus Genetics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Opus Genetics could also be used in its relative valuation, which is a method of valuing Opus Genetics by comparing valuation metrics of similar companies.Opus Genetics is currently under evaluation in net income category among its peers.
Opus Genetics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Opus Genetics from analyzing Opus Genetics' financial statements. These drivers represent accounts that assess Opus Genetics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Opus Genetics' important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 19.2M | 25.7M | 27.9M | 31.8M | 28.6M | 16.0M | |
| Enterprise Value | (4.8M) | (16.9M) | (22.7M) | 1.5M | 1.7M | 1.8M |
Opus Genetics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Opus Genetics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Opus Genetics' managers, analysts, and investors.Environmental | Governance | Social |
Opus Fundamentals
| Return On Equity | -3.39 | ||||
| Return On Asset | -0.61 | ||||
| Operating Margin | (2.70) % | ||||
| Current Valuation | 146.8 M | ||||
| Shares Outstanding | 68.96 M | ||||
| Shares Owned By Insiders | 14.23 % | ||||
| Shares Owned By Institutions | 27.62 % | ||||
| Number Of Shares Shorted | 728.36 K | ||||
| Price To Book | 29.59 X | ||||
| Price To Sales | 13.24 X | ||||
| Revenue | 10.99 M | ||||
| Gross Profit | (12.79 M) | ||||
| EBITDA | (57.52 M) | ||||
| Net Income | (57.53 M) | ||||
| Total Debt | 18.84 M | ||||
| Book Value Per Share | 0.09 X | ||||
| Cash Flow From Operations | (25.58 M) | ||||
| Short Ratio | 1.39 X | ||||
| Earnings Per Share | (1.86) X | ||||
| Target Price | 7.73 | ||||
| Number Of Employees | 18 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 193.79 M | ||||
| Total Asset | 36.86 M | ||||
| Retained Earnings | (139 M) | ||||
| Working Capital | 25.32 M | ||||
| Net Asset | 36.86 M |
About Opus Genetics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Opus Genetics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Opus Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Opus Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| HITI | High Tide | |
| HITI | High Tide | |
| BAC | Bank of America |
Check out Opus Genetics Piotroski F Score and Opus Genetics Altman Z Score analysis. For information on how to trade Opus Stock refer to our How to Trade Opus Stock guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opus Genetics. If investors know Opus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opus Genetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.86) | Revenue Per Share | Quarterly Revenue Growth (0.20) | Return On Assets | Return On Equity |
The market value of Opus Genetics is measured differently than its book value, which is the value of Opus that is recorded on the company's balance sheet. Investors also form their own opinion of Opus Genetics' value that differs from its market value or its book value, called intrinsic value, which is Opus Genetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opus Genetics' market value can be influenced by many factors that don't directly affect Opus Genetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opus Genetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Opus Genetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opus Genetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.